14–16mg
Daily vitamin need
Essential; almost everyone gets this from food already
Beat Zetia
Niacin vs. a patented drug
ARBITER 6-HALTS: niacin reversed artery thickening; ezetimibe (Zetia) didn't — trial stopped early for niacin
~$5–15
Niacin/month vs. PCSK9 injectable
Repatha/Praluent list price: $14,100/yr in 2015, cut to $5,850/yr in 2018 only after public pressure
Liver risk
Real, at the high dose — genuine
Sustained-release high-dose niacin can cause real hepatotoxicity. This is not disputed. Read the safety section.
The single biggest source of confusion about niacin: the ~15 mg/day your body needs as a vitamin and the 1,000–2,000 mg/day dose once used against heart disease are roughly 100× apart. Mixing them up is how people either dismiss a real medical option or mega-dose something with genuine toxicity. This page keeps them separate throughout.
#1 — THE VITAMIN
Essential
~15 mg/day prevents pellagra (the "4 D's": dermatitis, diarrhea, dementia, death). Rock-solid, settled nutrition science. Almost no one in a developed country is deficient.
#2 — THE HIGH-DOSE HEART DRUG
Contested — and abandoned
1,000–2,000 mg/day raises HDL more than anything else known, cut heart attacks and total mortality in the largest trial ever run on it (the Coronary Drug Project) — then was walked away from as patented alternatives arrived.
#3 — THE REAL RISK
Liver toxicity
At the high dose, especially sustained-release forms, niacin can genuinely damage the liver. This is documented, not a scare tactic — and it's why any high-dose use belongs under a doctor's monitoring.
According to PubMed, niacin's cardiovascular case is not "one failed drug" — it's a stack of mostly-positive monotherapy evidence, one head-to-head win against a patented drug, and two negative add-on trials whose design is worth scrutinizing before taking their headline at face value.
As a vitamin
Prevents pellagra; not in question
Coronary Drug Project
Monotherapy: fewer MIs, lower 15-yr all-cause mortality
ARBITER 6-HALTS
Niacin beat ezetimibe (Zetia) on artery thickness; stopped early for niacin's benefit
AIM-HIGH / HPS2-THRIVE
Add-on-to-statin trials found no extra benefit — design questions below
Long before PCSK9 inhibitors existed, niacin had the longest, largest outcome-trial record of any HDL-raising therapy ever tested.
Coronary Drug Project
↓ MI, ↓ mortality
The largest niacin-monotherapy outcome trial run: fewer recurrent heart attacks during the trial, and a 15-year follow-up found significantly lower all-cause mortality in the group originally randomized to niacin.
ARBITER 6-HALTS — niacin vs. a patented drug
Niacin won
Head-to-head against ezetimibe (brand name Zetia, patented): niacin significantly regressed carotid artery thickness; ezetimibe did not. The trial was stopped early because niacin's benefit was already clear.
Six major CV-outcome trials, reviewed
Mostly positive
A review of niacin's six major cardiovascular trials found significant benefit in all but one (a trial in patients who started with normal cholesterol) — "strong and consistent evidence," in the reviewer's words.
Then the patent math changed
$3.4B bet
Abbott paid $3.4 billion for Kos Pharmaceuticals in 2006 to own Niaspan (patented extended-release niacin), which was pulling in over $900M/year. The value was in the patented delivery form, not the cheap generic vitamin itself.
Two things happened in the same window: the trials that killed niacin's guideline status were run and published, and a new class of patented injectable cholesterol drugs launched at a price niacin could never touch.
| What happened | Year | The money angle |
|---|
| AIM-HIGH stopped early, "no added benefit" on niacin + statin | 2011 | Patients already at LDL goal on statins; a ceiling effect by design was a criticized limitation of the trial |
| HPS2-THRIVE: no benefit, more side effects | 2014 | Tested niacin bundled with laropiprant, Merck's own patented anti-flushing add-on — not niacin alone |
| FDA withdraws approval for niacin+statin combo products | 2016 | Guidance follows the two add-on trials above; Niaspan, Advicor, Simcor pulled |
| PCSK9 inhibitors (Repatha, Praluent) launch | 2015 | List price $14,100/year — a patented biologic with no generic competition |
| PCSK9 list price cut 60% | 2018–2024 | To $5,850/year — only after years of insurer pushback and public pressure on the original price |
The honest math: generic niacin runs roughly $5–15 a month. A PCSK9 inhibitor, even after a 60% list-price cut forced by public pressure, runs about $5,850 a year — still tens of times more, before the cut it was $14,100/year. Nobody holds a patent on niacin; a $3.4B acquisition and two blockbuster biologic franchises rode on cholesterol drugs that competed directly with a vitamin store staple. That doesn't prove the negative trials were rigged. It does mean the parties who profit most from "niacin doesn't work" are not neutral, and the two trials that sealed that verdict tested niacin bundled with a patented add-on (laropiprant) or in patients already at their statin goal — not niacin alone, in people who actually needed it. Interrogate the design before accepting the headline.
All you need
Food (meat, fish, grains)
$0
covers the RDA
Niacin supplement, low dose
~$5
per month
Doctor-monitored
High-dose (1–2g) niacin
$10–40
per month; needs liver monitoring
PCSK9 inhibitor (patented)
$5,850
per year, list price after 2018–24 cuts (was $14,100)
The gap between the vitamin dose and the trial dose is the whole story — keep them straight.
RDA (vitamin)
14–16 mg/day
What your body needs — routinely covered by a normal diet
Tolerable upper limit
35 mg/day
From supplements; flushing starts above this
Coronary Drug Project / ARBITER dose
1,000–2,000 mg/day
~100× the vitamin dose — the studied cardiovascular dose, extended-release
Don't
Self-mega-dose
High-dose niacin is a monitored medical decision with real liver risk — never a casual "more is better" supplement
This is not a compound where the establishment invented a risk to protect a patent. High-dose niacin has genuine, well-documented toxicity. Read this section before considering the high dose.
Liver toxicity is real
Documented
Case reports describe sustained-release niacin causing marked liver-enzyme elevation, focal fatty liver on imaging, and even coagulopathy — resolving after stopping the drug. Sustained-release forms carry the highest liver risk.
→ Coppola et al. 1994,
South Med J, PMID
8284714 · Durham et al. 2018,
J Am Pharm Assoc,
DOIPeople have hurt themselves misusing it
Not theoretical
A documented case: an HIV-positive patient took high-dose over-the-counter sustained-release niacin trying to beat a urine drug test (a claim with no scientific basis) and developed liver enzymes over 25× normal. It resolved after stopping niacin — but this is a real-world harm from real-world misuse.
→ Durham et al. 2018,
J Am Pharm Assoc ·
DOI · PMID
29941333The flush is real too
Prostaglandin-driven
Therapeutic doses trigger an intense skin flush via the GPR109A receptor, which releases prostaglandin D2 and causes visible cutaneous vasodilation. Uncomfortable, generally not dangerous — but it's the main reason patients quit the drug.
→ Javaid & Mudavath 2024,
Arch Biochem Biophys ·
DOI · PMID
39322100
Also worth weighing honestly: a 2024 Cleveland Clinic metabolomics study (n = 4,000+ across three cohorts) found that the terminal breakdown products of excess niacin (called 2PY and 4PY) were associated with roughly double the 3-year risk of a major cardiac event, and that 4PY triggered vascular inflammation in mice. This does not erase the Coronary Drug Project or ARBITER 6-HALTS results, but it is a real, independent, non-industry-funded signal that mega-dosing niacin beyond what your body needs may carry its own cardiovascular downside — on top of the liver risk. Report it plainly; don't wave it away because it's inconvenient to the "follow the money" story.
Bottom line on safety: getting your B3 from food is completely safe, full stop. High-dose niacin (1–2g/day) for cholesterol is a real medical option with a real outcome-trial track record — and real liver toxicity, real flushing, and a real 2024 harm signal from its own breakdown products. This is a monitored medical decision made with a doctor and periodic liver-enzyme checks, never a self-directed "more is better" supplement.
FDA
Withdrew the statin-combo approval
In 2016 the FDA withdrew approval for niacin-plus-statin combination products (Niaspan, Advicor, Simcor), citing AIM-HIGH and HPS2-THRIVE. Niacin itself remains legally sold over the counter as a supplement.
Cardiology guideline bodies
No longer routine add-on
Major guidelines stopped recommending niacin added to statins after the two add-on trials — a position built on trials whose design (statin-goal ceiling; laropiprant bundling) is itself contested above. This is their position, not a proven fact of biology.
→ Boden et al. 2013,
J Cardiovasc Pharmacol Ther,
DOI
The patients who used niacin alone
The Coronary Drug Project + ARBITER cohorts
Where niacin was tested alone (not bundled with a patented add-on, not capped by a statin already at goal), it reduced heart attacks, reduced 15-year mortality, and beat a patented drug on artery thickness.
The 2024 harm-signal researchers
Caution on excess niacin
Cleveland Clinic researchers who found the 4PY/inflammation link are not pharma-funded lipid-drug marketers — their caution about mega-dosing is a genuinely independent signal, not an industry talking point, and deserves to be weighed on its own evidence.
→ Ferrell/Hazen 2024,
Nat Med,
DOI
Not controlled evidence — labeled and weighted accordingly.
"The flush feels like proof it's working"
Just the flush
The hot, red, tingling flush is a blood-vessel/prostaglandin reaction, not evidence of cholesterol benefit — and "flush-free" no-flush niacin forms carry higher liver risk, not lower.
Statin-intolerant patients seeking an alternative
A real gap
Some people can't tolerate statins (myopathy, myalgia) and look for another lever on cholesterol. Niacin's own trial record makes it a legitimate option to discuss with a doctor — not a scam, not a miracle either.
NAD+/longevity crowd
Re-examining
B3 forms (niacin, NR, NMN) are popular for "boosting NAD+." The 2024 4PY finding made many in that space reconsider pushing plain niacin to high doses specifically.
The Bottom Line — In Plain English
What it is: An essential vitamin (~15 mg/day, easily covered by food) that, at a roughly 100× higher dose, was also one of the best-studied cholesterol drugs of the 20th century.
What the real record shows: Used alone, high-dose niacin cut heart attacks, cut 15-year mortality, and out-performed a patented drug (ezetimibe) on artery thickness in a head-to-head trial stopped early for niacin's benefit. The two trials that killed its guideline status tested it bundled with a patented add-on or in patients whose cholesterol was already controlled — a design worth questioning, not a closed case.
Follow the money: A generic vitamin nobody can patent lost guideline standing in the same years a $14,100/year patented injectable class launched. That contrast doesn't prove a conspiracy — it does mean "the trials say no" deserves a closer read of who funded and designed them, not blind acceptance.
The honest safety line, stated bluntly: the high dose carries real, documented liver toxicity, an intense flush most people can't tolerate long-term, and a genuine 2024 signal that excess niacin's own breakdown products may add cardiovascular risk through inflammation. This is not a whitewash page — the danger is real and this is a doctor-monitored decision, not a self-directed supplement.
- As a vitamin, niacin is essential and effectively risk-free at food-level intake.
- As a cardiovascular drug, its monotherapy trial record is genuinely strong — including beating a patented competitor head-to-head.
- The negative add-on trials (AIM-HIGH, HPS2-THRIVE) have real design limitations that get glossed over when cited as a flat "niacin doesn't work."
- Niacin's fall from guideline favor tracks suspiciously well with the arrival of two blockbuster patented alternatives priced 100× to 1,000× higher — a pattern worth naming out loud.
- High-dose liver toxicity and a 2024 inflammation/harm signal from excess niacin are real and documented — this is genuinely not a "perfectly safe, why isn't everyone taking it" story. Any high dose belongs under a doctor's care with liver-enzyme monitoring.